Trial Profile
The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Mar 2023
Price :
$35
*
At a glance
- Drugs Zelavespib (Primary)
- Indications Lymphoma; Myeloproliferative disorders; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics
- 08 Jun 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.
- 08 Jun 2022 Planned primary completion date changed from 1 Jul 2022 to 1 Jul 2023.
- 08 Jun 2021 Planned End Date changed from 1 Jul 2021 to 1 Jul 2022.